ThermoGenesis Holdings Inc. (THMO): רווח נקי למניה (EPS TTM)
A liquidity crisis and strategic uncertainty are hindering software monetization, as evidenced by ThermoGenesis (THMO) TTM net income per share distribution. The value of -4.72 indicates the level of this metric. However, its status as a standard in cell therapy allows ThermoGenesis (THMO) to exercise pricing power over its equipment. An impeccable B2B image and the trust of the scientific community solidify the brand's position within the biobanking sector.
פילוחים אנליטיים ודוחות נתונים של חברת ThermoGenesis Holdings, Inc. (THMO)
ThermoGenesis is scaling B2B implementation of biobanking and cell culture systems to expand into the diagnostics segment. The TTM net income per share, equal to -4.72, measures the portion of profit allocated to each common share over the year. This metric strips out the influence of capital structure, allowing for an assessment of the business's actual efficiency. The TTM net income per share trend reflects the company's reaction to structural market shifts, which determines the fundamental stability of the asset's current market value.
